We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current ALGEN market cap is 32.09M. The company's latest EPS is EUR 0.1690 and P/E is 20.47.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 13.02M | 14.51M | 17.92M | 19.8M | 25.37M |
| Operating Income | -641k | -307k | -530k | 991k | 3.78M |
| Net Income | -1.04M | -687k | -322k | 778k | 1.57M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 19.15M | 27.57M | 32.66M | 32.92M | 31.84M |
| Total Liabilities | 12.31M | 18.57M | 17.94M | 16.76M | 14.46M |
| Total Equity | 6.84M | 9M | 14.72M | 16.17M | 17.38M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | N/A | -163k | -561k | N/A | N/A |
| Investing | N/A | -4.75M | -2.26M | N/A | N/A |
| Financing | N/A | 6.54M | 5.71M | N/A | N/A |
| Market Cap | 32.09M |
| Price to Earnings Ratio | 20.47 |
| Price to Sales Ratio | 1.27 |
| Price to Cash Ratio | 7.53 |
| Price to Book Ratio | 1.85 |
| Dividend Yield | - |
| Shares Outstanding | 9.27M |
| Average Volume (1 week) | 1.9k |
| Average Volume (1 Month) | 2.65k |
| 52 Week Change | -12.41% |
| 52 Week High | 4.69 |
| 52 Week Low | 2.88 |
| Spread (Intraday) | 0.12 (3.43%) |
| Company Name | Genoway S A Inh Eo 15 |
| Address |
31 rue saint jean de dieu lyon, rhone 69007 |
| Website | https://www.genoway.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
